A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
Saved in:
| Title: | A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. |
|---|---|
| Authors: | Bairey O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Taliansky A; Institute of Oncology, Neuro-Oncology Unit, Sheba Medical Center, Ramat Gan, Israel., Glik A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Neurology, Cognitive Neurology Clinic, Rabin Medical Center, Petach Tikva, Israel., Amiel A; Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel., Yust-Katz S; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel., Gurion R; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Zektser M; Institute of Hematology, Soroka Medical Center, Beer-Sheva, Israel., Porges T; Institute of Hematology, Soroka Medical Center, Beer-Sheva, Israel., Sarid N; Institute of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Horowitz NA; Department of Hematology and BMT, Rambam Health Care Campus, Haifa, Israel., Shina TT; Institute of Oncology, Neuro-Oncology Unit, Rambam Health Care Campus, Haifa, Israel., Lebel E; Department of Hematology, Hadassah Medical Center, Jerusalem, Israel.; Faculty of Medicine, Hebrew University, Jerusalem, Israel., Cohen A; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Geiger KR; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel., Raanani P; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Wolach O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Siegal T; Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Faculty of Medicine, Hebrew University, Jerusalem, Israel. |
| Source: | Cancer [Cancer] 2023 Dec 15; Vol. 129 (24), pp. 3905-3914. Date of Electronic Publication: 2023 Aug 12. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
